Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the lives of patients worldwide.
INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE
The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to further advance our lead candidate, OC-118, for commercialisation as a new therapeutic option for DME patients
and to develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets
OC-118 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT
Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
TAKING TREATMENT FROM INJECTIONS TO DROPS FOR BACK-OF-THE-EYE DISEASES
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
Location: Switzerland, Vaud, Lausanne
Employees: 11-50
Total raised: $192.47M
Founded date: 2017
Investors 4
Date | Name | Website |
- | Earlybird ... | earlybird.... |
- | VI Partner... | vipartners... |
- | NFLS - Piv... | pivotalbio... |
- | Bay City C... | baycitycap... |
Funding Rounds 5
Date | Series | Amount | Investors |
15.04.2024 | - | $59M | - |
12.06.2023 | - | $40M | - |
05.05.2021 | Series C | $57M | - |
04.01.2019 | Series B | $15.95M | - |
05.01.2018 | Series B | $20.52M | Novartis V... |
Mentions in press and media 45
Date | Title | Description | Source |
17.04.2024 | Oculis Shines Bright with $59 Million Funding Round | Oculis, a visionary biopharmaceutical company, has secured a dazzling $59 million in an oversubscrib... | parsers.vc... |
15.04.2024 | Oculis secures USD 59 Million in oversubscribed offering and... | Oculis secures USD 59 Million in oversubscribed offering and debuts on NASDAQ Iceland main market 15... | venturelab... |
12.04.2024 | Oculis raises $59 million in oversubscribed round | Oculis is a clinical stage biopharmaceutical company purposefully driven to save sight and improve ... | startuptic... |
22.12.2023 | Clinical progress for three Biotechs | startuptic... | |
10.10.2023 | Promising breakthroughs in healthcare | startuptic... | |
02.10.2023 | Leadership changes to fuel startup growth | startuptic... | |
17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals... | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metr... | tech.eu/20... |
14.07.2023 | Nasdaq-listed Lilium raises $192 million in shares sale and ... | Following the company’s announcement of intentions to raise $250 million back in May, Munich-based e... | tech.eu/20... |
12.06.2023 | Oculis secures USD 40 m | startuptic... | |
30.05.2023 | Positive results for Swiss biotechs’ clinical studies | startuptic... |
Show more